Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Blum Robert I

Malik Fady Ibraham

Lee Sung

Callos Andrew

Kaye Edward M. MD

Cytokinetics announced it will report second quarter 2026 results on August 6, 2026, followed by a conference call at 4:30 PM ET. The company highlighted positive topline results from its ACACIA-HCM Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy patients and plans to discuss findings with regulatory authorities.

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Investor with bios & tech focus. Tweets are my opinions only and not investment advice. May have positions short or long term on stocks I tweet.

Bios_n_Techs

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Cytokinetics Inc (CYTK) Stock Price, Analysis & Trade Signals